Abstract

Amelioration of Insulin, Leptin and Adiponectin Levels in Experimental Metabolic Syndrome Model by Some Drugs

Author(s): N. M. Al-Rasheed, H. M. Abdelkarem, L.M. Fadda, A. M. Mohamed, N. M. Al-Rasheed, Y. Bassiouni, H. M. Ali* and A. H. Gafeer
Department of Pharmacology, College of Pharmacy, 1Department Chemistry, Faculty of Science Aljouf University, Sakaka, 2Department of Nutrition, National Research Center, Dokki, Egypt, 3Biochemistry Department, Faculty of Science - Al Faisaliah, King Abdulaziz University, Jeddah, 4Therapeutic Chemistry Department, 5Department of Genetics and Cytology; National Research Center, Dokki, Egypt, 6Preparatory Year Deanship; King Saud University, Riyadh-KSA

Correspondence Address:
Preparatory Year Deanship; King Saud University, Riyadh-KSA E-mail: [email protected]


A comparative study was planned to explore the modulating impact of metformin, lipitor or orlistat against the metabolic syndrome components, including hyperglycemia and hyperlipidemia. Also, the effects of these drugs on leptin and adiponectin as biomarkers of metabolic syndrome in a rat model were investigated for the first time. The administration of these drugs each alone to metabolic syndrome induced rats markedly ameliorated the increase in blood glucose, normalized the serum insulin and the high density lipoprotein cholesterol levels and reduced triglyceride, total cholesterol and low density lipoprotein cholesterol. The alterations in serum leptin and adiponectin levels in metabolic syndrome induced rats were significantly modulated by these drugs. Metformin was the most effective drug in modulating most of the studied parameters.



Share this  Facebook  Twitter  LinkedIn  Google+